Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Compositions and methods for inhibiting expression of mutant EGFR gene
US9212364B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9212364-B2 |
| Application number | US-201213659315-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 24, 2012 |
| Priority date | Sep 2, 2008 |
| Publication date | Dec 15, 2015 |
| Grant date | Dec 15, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.
First claim
Opening claim text (preview).
We claim: 1. A method of treating glioblastoma multiforme (GBM), the method comprising administering to a human in need of such treatment a therapeutically effective amount of a first double-stranded ribonucleic acid (dsRNA) and a second dsRNA, wherein the first dsRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region of complementarity which is 19-24 nucleotides in length and which is fully complementary to at least a part of an mRN…
Assignees
Inventors
Classifications
- C12N15/1138Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9212364B2 cover?
- The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.
- Who is the assignee on this patent?
- Sah Dinah, Tan Pamela, Cavenee Webster, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1138. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).